Delcath Systems (DCTH) Stock Price, News & Analysis

Company Overview

Delcath Systems, Inc. is a commercial-stage oncology company focused on liver-directed therapies for patients with metastatic cancer. Its technology is designed to deliver high concentrations of chemotherapy directly to the liver while limiting systemic exposure, addressing cancers that are difficult to treat with conventional approaches.

The company’s primary products are HEPZATO (melphalan for injection) and the HEPZATO KIT in the United States, as well as CHEMOSAT in markets outside the United States. The system is used with percutaneous hepatic perfusion, a procedure in which the liver is temporarily isolated from the general bloodstream, treated with chemotherapy, and then the blood is filtered before being returned to the patient.

In the United States, HEPZATO is approved for certain adult patients with unresectable hepatic-dominant metastatic uveal melanoma. Delcath also markets CHEMOSAT in Europe and other international markets for liver-directed treatment of metastatic liver cancers, subject to local regulatory requirements. The company’s products are administered at specialized treatment centers by trained medical professionals.

Key Stats

• Today's Range: $14.00 to $14.83
• 50-Day Range: $14.72 to $17.36
• 52-Week Range: $8.12 to $17.42
• Volume: 383,853 shs
• Average Volume: 462,009 shs
• Market Capitalization: $488.58 million
• P/E Ratio: 1,409.41
• Dividend Yield: N/A
• Price Target: $23.17
• Consensus Rating: Moderate Buy

Delcath Systems Stock Analysis - MarketRank™

Delcath Systems scored higher than 75% of companies evaluated by MarketBeat, and ranked 284th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Delcath Systems has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Delcath Systems has a consensus price target of $23.17, representing about 64.5% upside from its current price of $14.08.

Amount of Analyst Coverage

Delcath Systems has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Delcath Systems are expected to grow in the coming year, from ($0.17) to $0.12 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Delcath Systems is 1,409.41, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.70.

Price to Earnings Ratio vs. Sector

The P/E ratio of Delcath Systems is 1,409.41, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.15.

Price to Book Value per Share Ratio

Delcath Systems has a P/B Ratio of 4.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.96% of the float of Delcath Systems has been sold short.

Short Interest Ratio / Days to Cover

Delcath Systems has a short interest ratio ("days to cover") of 5.37.

Change versus previous month

Short interest in Delcath Systems has recently decreased by 15.78%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Delcath Systems does not currently pay a dividend.

Dividend Growth

Delcath Systems does not have a long track record of dividend growth.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: 1.58

News Sentiment

Delcath Systems has a news sentiment score of 1.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Delcath Systems this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for DCTH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

6 people have added Delcath Systems to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Delcath Systems insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.36% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.12% of the stock of Delcath Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:DCTH
• CIK: 872912
• Web: delcath.com
• Phone: 212-489-2100
• Fax: 212-489-2102
• Employees: 156
• Year Founded: 1988

Price Target and Rating

• Average Price Target for Delcath Systems: $23.17
• High Price Target: $32.00
• Low Price Target: $18.00
• Potential Upside/Downside: +64.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.01
• Trailing P/E Ratio: 1,409.41
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $2.70 million
• Net Margins: 0.56%
• Pretax Margin: 1.35%
• Return on Equity: 0.46%
• Return on Assets: 0.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.83
• Quick Ratio: 8.95

Sales & Book Value

• Annual Sales: $85.23 million
• Price / Sales: 5.73
• Cash Flow: $0.05 per share
• Price / Cash Flow: 281.59
• Book Value: $3.15 per share
• Price / Book: 4.47

Miscellaneous

• Outstanding Shares: 34,700,000
• Free Float: 27,981,000
• Market Cap: $488.58 million
• Optionable: Optionable
• Beta: 0.60